 REDWOOD CITY, Calif., Oct. 01, 2021 GLOBE NEWSWIRE -- Coherus BioSciences, Inc. Coherus, Nasdaq: CHRS today announced the United States Food and Drug Administration FDA has accepted for review the 351k Biologics License Application BLA for CHS-201, a biosimilar candidate of reference product Lucentis ranibizumab. The FDA has set a Biosimilar User Fee Act action date for August 2, 2022, and, if approved, Coherus plans to launch the Lucentis biosimilar in the U.S. in the second half of 2022. The BLA for CHS-201 also known as FYB201 was submitted by Coherus partner, Bioeq AG, from whom Coherus acquired U.S. commercial rights in 2019. 